Scilex Holding (SCLX) Depreciation and Depletion (2022 - 2026)
Scilex Holding (SCLX) recorded quarterly Depreciation and Depletion of $800000.0 in Q1 2026, up 215.08% quarter-over-quarter from $253900.0 in Q4 2025, and up 79900.0% on a YoY basis from N/an in Q1 2025.
Scilex Holding (SCLX) Depreciation and Depletion (2022 - 2026) Analysis & Trends
Scilex Holding's Depreciation and Depletion history runs 5 years deep, the most recent figure standing at $800000.0 for Q1 2026.
- In Q1 2026, Depreciation and Depletion rose 79900.0% year-over-year to $800000.0; the TTM figure through Mar 2026 stood at $1.1 million (up 9517.27% YoY), while the FY2025 annual figure was $258900.0, up 1749.29% from the prior year.
- Depreciation and Depletion was $800000.0 for Q1 2026 at Scilex Holding, up from $253900.0 in the prior quarter.
- In the past five years, Depreciation and Depletion ranged from a high of $800000.0 in Q1 2026 to a low of $1000.0 in Q1 2025.
- Historically, Depreciation and Depletion has averaged $68405.9 across 5 years, with a median of $10000.0 in 2022.
- The sharpest annual moves came in 2024 and 2026: Depreciation and Depletion sank 75.0% in 2024, then jumped 79900.0% in 2026.
- A 5-year view of Depreciation and Depletion shows it stood at $10000.0 in 2022, then dropped by 20.0% to $8000.0 in 2023, then tumbled by 75.0% to $2000.0 in 2024, then surged by 12595.0% to $253900.0 in 2025, then jumped by 215.08% to $800000.0 in 2026.
- The last three Depreciation and Depletion figures came in at $800000.0 (Q1 2026), $253900.0 (Q4 2025), and $2000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | 188.00 Mn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | 581.00 Mn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 93.00 Mn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | 139.00 Mn |
| 10 | Scilex Holding | 58.57 Mn | -91.35 Mn | 4.15 Mn | 800,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 800,000.00 |
| Mar 31, 2026 | 800,000.00 |
| Dec 31, 2025 | 253,900.00 |
| Dec 31, 2025 | 253,900.00 |
| Sep 30, 2025 | 2,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Sep 30, 2024 | 4,000.00 |
| Sep 30, 2024 | 4,000.00 |
| Jun 30, 2024 | 4,000.00 |
| Jun 30, 2024 | 4,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Dec 31, 2023 | 8,000.00 |
| Dec 31, 2023 | 8,000.00 |